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Abstract Membrane molecules such as CD36 (OKM5),
intercellular adhesion molecule-1 (ICAM-1, CD54),
gamma interferon-induced protein 10 (ç-IP10) and IL-
1 are induced and/or upregulated in psoriatic epider-
mis. These molecules have important accessory, traf-
ficking or signalling functions in the immune system
and also play a role in the pathophysiology of psoria-
sis. The relevance of adhesion molecules, CD36 and
epidermal IL-1 in psoriasis was studied in vitro in the
autologous mixed epidermal cell – T lymphocyte reaction
(MECLR). Their level of expression was quantitated in
epidermal cell suspensions (ECS) from patients with
psoriasis and their function was assessed by blocking
with specific mAbs and antisera or by depleting CD36+
cells from the ECS prior to the MECLR. ECS from
psoriatic lesions contained increased numbers of CD36+
(23 ± 12%), ICAM-1+ (31 ± 14%) and IL-1+ (57 ± 21%)
cells. The autologous MECLR was inhibited in samples
from all patients by mAb to CD2 (LFA-2), CD11a
(LFA-1Æ), CD18 (LFA-1â), ICAM-1, CD58 (LFA-3) and
an antiserum to IL-1â. Thus, adhesion molecules facili-
tate inflammation in psoriasis not only via adhesion and
recruitment of T lymphocyte in psoriatic lesions, but also
via activation of T cells. Furthermore CD36 molecules on
psoriatic epidermal cells do not costimulate autologous T
lymphocytes in psoriasis. The observed costimulatory
function of IL-1â in the MECLR emphasizes its rele-
vance in psoriasis.
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Introduction
The autologous mixed epidermal cell-T lymphocyte reac-
tion (MECLR) is elevated in psoriasis patients [21]. This
is mainly due to the spontaneous stimulation of autolo-
gous T lymphocytes by HLA-DR+/CD1a– epidermal anti-
gen-presenting cells (APC) in the absence of exogenously
added antigen [19]. Cytokines produced by activated T
lymphocytes may induce the ‘psoriatic phenotype’ and
upregulate the expression of gamma interferon-induced
protein 10 (γ-IP10), HLA-DR, ICAM-1 (CD54) and
CD36 (OKM5, thrombospondin receptor) on keratino-
cytes [1, 15]. Epidermal cells (EC) from psoriatic lesions
do indeed express increased levels of CD36, ICAM-1 and
γ-IP10 [2, 3, 10, 11].
In psoriatic lesions, CD36 is intensely expressed on
keratinocytes, sporadically on intraepidermal dendritic
cells and consistently on dermal dendritic and endothelial
cells [3]. Peripheral blood CD36+/CD11b– monocytes are
potent stimulators of autologous T lymphocytes in the au-
tologous mixed lymphocyte reaction (MLR) [22]. Epider-
mal CD36+/CD11b– APC have also been shown to be ef-
ficient stimulators of autologous T lymphocytes [1].
However, the proportion of such APC is low and is in-
creased in healthy human skin only after irradiation with
3 to 5 MED UVB [1]. Based on the crucial role of CD36+
APC in the MLR, it is considered possbile that CD36+ EC
from psoriatic lesions could serve as accessory cells in the
autologous MECLR [1, 6, 26].
The integrins CD11a (LFA-1α), CD18 (LFA-1β) and
their ligands have been shown to be crucial for successful
(allo)antigen and mitogen-induced T-cell activation and
proliferation [13]. Costimulation via adhesion molecules
on epidermal APC is essential for effective antigen-spe-
cific T-cell proliferation [16, 20]. The LFA-1/ICAM-1 ad-
hesion pathway may be involved in the pathogenesis of
psoriasis by facilitating lymphocyte adhesion, trafficking,
activation and stimulation [15]. The expression of IL-1 is
abnormal in psoriatic lesions [8, 18]. IL-1 is known to
costimulate T lymphocytes during antigen presentation
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[14]. In the study reported here, the expression of the
above-mentioned molecules was quantified and their func-
tion in psoriasis was investigated.
Materials and methods
Patients and controls
Patients with stable untreated, plaque-type psoriasis underwent
shave biopsies and venipuncture after informed consent had been
obtained. The autologous MLR and the MECLR were performed
with samples from all patients. The number of patients samples of
which were tested in each experiment is shown in Tables 2 and 3 and
Figs. 1 and 2. EC and peripheral blood mononuclear cells (PBMC)
were immunophenotyped. EC isolated from uninvolved skin of
nickel dermatitis patients and from patients undergoing abdominal
or breast plastic surgery served as controls. Isolated PBMC from
these patients and other healthy individuals served also as controls.
Preparation of epidermal cell suspensions
Split-skin specimens from involved skin of psoriasis patients and
from excised skin of controls were obtained using a dermatome. In
nickel dermatitis patients, blister roofs were obtained using the
suction blister technique [20]. Single cell suspensions of EC were
prepared using standard methods [19]. Briefly, split-skin speci-
mens were rinsed with phosphate-buffered saline (PBS), cut into
pieces of ± 0.5 cm2 and floated in Ca2+- and Mg2+-free PBS con-
taining 0.0625% trypsin (ICN, Cleveland, Ohio, USA) and 0.1%
EDTA for 45 min at 37°C in an atmosphere containing 5% CO2,
and in the presence of 0.025% deoxyribonuclease solution (DNase;
Sigma, St. Louis, Mo., USA) during the last 15 min of the incuba-
tion. Epidermal sheets were separated from the dermis using fine
forceps, cut with scissors and the EC were filtered through sterile
100-µm and 30-µm mesh nylon gauzes and resuspended in RPMI-
1640 supplemented with antibiotics, fresh L-glutamine, 20 mM
Hepes (RPMI complete medium), 20% heat-inactivated human AB
serum and 0.01% DNase. Cells were counted using a haemocyto-
meter and their viability was determined by trypan blue exclusion.
Removal of CD36+ cells from epidermal cell suspensions
CD36+ cells were removed from the epidermal cell suspensions
(ECS) using anti-CD36 mAb (Table 1) and antimouse Ig-conju-
gated paramagnetic beads (Dynal, Oslo, Norway) [17]. Briefly,
ECS were incubated for 30 min at 4°C with primary mAb, rinsed
three times, incubated with the conjugated paramagnetic beads and
centrifuged. After 30 min the pellet was resuspended and the
rosettes counted. Rosetted cells were attracted to one side of the
tube by a strong magnet and the non-rosetted cells were collected.
The number of rosetted cells was compared with the number of
CD36+ EC before depletion and the efficiency of the depletion was
checked again later by immunofluorescent staining. In pilot exper-
iments IgG1 isotype control mAb was used as the first step fol-
lowed by the normal immunomagnetic separation procedure.
Isolation of peripheral blood mononuclear cells 
and purification of T lymphocytes.
PBMC were isolated using density gradient centrifugation on
Lymphoprep (density 1.077; Nyegaard, Oslo, Norway). All rinsing
and isolating of other cells was done in RPMI complete medium
containing 1% human AB serum. FCS was not used in this study.
T lymphocytes were isolated with a rosetting technique using
2-aminoethylisothiouronium bromide (AET)-treated sheep red
blood cells. These purified cells consisted of approximately 95%
CD3+, 99% CD2 (OKT11)+, 0–0.5% CD14+ and 0–0.5% CD20+
cells [17, 18]. The accessory capacity of this fraction was negligible
because this population could not be stimulated by antigen alone
[2, 13].
Monoclonal antibodies and immunophenotyping 
of cell suspensions
In addition to the mAbs in Table 1, the following mAbs were used
for immunophenotyping: CD3 (Leu-4), CD4 (Leu-3), CD5 (Leu-1),
CD8 (Leu-2), CD16 (Leu-11b), CD25 (IL-2 receptor α chain; Bec-
ton Dickinson), CD20 (B1; Coulter, Hialeah, Fl., USA), CD11b (CR3,
OKM1), CD36 (OKM5; Ortho Diagnostic), CD71 (66IG10; Dr.
M. van der Rijn, Amsterdam), CD14 (My4; Dr. J. D. Griffin,
Boston, Mass., USA), CD15 (VIM-D5; Dr. W. Knapp, Vienna),
CD29 (VLA-β1, 4B4; Coulter), CD45 (HLe-1, FITC-conjugated;
Becton Dickinson), CD45RA (2H4; Coulter), IL-1β (Cistron, Pine
Brook, N.J., USA) and TcR-γδ (11F2; Dr. J. Borst, Amsterdam).
Immunophenotyping of EC, PBMC or whole blood samples was
performed using direct, indirect and double-labelling (SimulSET)
immunofluorescence techniques and flow cytometry as described
by Van Dongen et al. [28]. CD36/CD45 double-labelling of ECS
was carried out by the addition of rhodamine-labelled goat-anti-
mouse IgG to detect the primary OKM5 mAb, and incubation with
10% normal mouse serum followed by HLe1-FITC mAb. Double-
labelling of PBMC was also performed to detect CD3/CD4, CD3/
CD8, CD3/CD25 and CD3/HLA-DR double-positive cells accord-
ing to standard procedures (SimulSET). The FACscan data were
analysed using the SimulSET and Lysis programs (Becton Dickin-
son). The results were expressed as the mean percentage ± SD.
Autologous MECLR and MLR
Mixed cultures of unpurified EC and PBMC or purified T lym-
phocytes were set-up in quadruplicate in round-bottomed mi-
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Table 1 Source and speci-
ficity of antibodies used in de-
pletion and blocking experi-
ments. Mouse IgG1 (10 µg/ml)
and IgG2a (1 µg/ml) isotype
control mAbs, and normal goat
and normal rabbit sera at a di-
lution of 1/100 were used as
controls
mAb Source Specificity Isotype Final
concentration
CLB-LFA1/2 Central Blood Transfusion Laboratory LFA-1α/CD11a IgG1 10 µg/ml
CLB LFA1/1 Central Blood Transfusion Laboratory LFA-1β/CD18 IgG1 10 µg/ml
OKT11 Ortho Co. LFA-2/CD2 IgG2a 1 µg/ml
TS 2/9 T.S. Springer LFA-3/CD58 IgG1 1 µg/ml
RR1/1.1.1 R.R. Rothlein ICAM-1/CD54 IgG1 1 µg/ml
HLA-DR Becton Dickinson – IgG2a 0.25 µg/ml
OKM5 Ortho Co. CD36 IgG1 1 µg/ml
Polyclonal antibodies
α-IL-1β Van Damme et al. [27] Human IL-1β – 1/1000
α-IL-6 Helle et al. [12] Human IL-6 – 1/1000
70
crotitre plates (Costar, Cambridge, Mass., USA). To each well, 4 ×
104 EC and 1–2 × 105 PBMC were added to a final volume of 0.2
ml complete RPMI medium supplemented with 15% human AB
serum. The autologous MLR comprised the spontaneous prolifera-
tion of separately plated fractions of PBMC. Only non-irradiated
EC were used because we had previously shown that autologous
MECLR responses with non-irradiated EC did not differ signifi-
cantly from those with irradiated EC [19]. The cultures were pulsed
with 18.5 kBq tritiated thymidine ([3H]TdR, 185 GBq/mmol;
Amersham, UK) on days 6, 7 and 8 and harvested 8 h later onto
glass fibre filters. The amount of incorporated [3H]TdR was deter-
mined by liquid scintillation counting (β-plate; Pharmacia/LKB,
Uppsala, Sweden). The results were expressed as mean ± SEM
counts per min (cpm) of quadruplicate cultures.
Blocking of the autologous MECLR with antibodies
The mAbs used in the blocking experiments are shown in Table 1.
Sodium azide (NaN3) was removed from all mAbs by overnight
dialysis at 4°C. Anti-HLA-DR mAb was used as a positive con-
trol, and a mAb to an irrelevant epitope (anti-CD14, My4) as well as
IgG1 and IgG2a mouse isotype control mAbs (Becton Dickinson)
were used as negative controls in the blocking experiments. The
IL-1 antiserum (2580) was raised in a rabbit by immunization with
highly purified natural human IL-1β. It contained no preservatives
and has been shown to neutralize natural and human recombinant
IL-1β (Dr. J. Van Damme, Leuven) [27]. At our laboratory this anti-
serum (dilution 1/16 000) completely neutralized 2.5 IU/ml rIL-1β
in the D10N bioassay. The antiserum to IL-6 was raised in a goat
by immunization with human recombinant IL-6 and has been
shown to neutralize natural and recombinant human IL-6 (Dr. M.
Helle and Prof. L. Aarden, CLB, Amsterdam) [12]. This antiserum
(dilution 1/16000) completely neutralized 5 IU rIL-6/ml in the B9
bioassay. The EC were preincubated with the antibodies prior to
adding PBMC.
Blocking with mAb of in vitro T-lymphocyte proliferation 
to control antigens
Pure tetanus toxin (from Clostridium tetani), without preservatives
or aluminium hydroxide; Calbiochem, San Diego, Calif., USA) was
used at a final concentration of 3 µg/ml. Concanavalin A (Con-A)
type IV-S (Sigma Chemical Co.) was used at a final concentration
of 10 µg/ml in the cultures. Nickel sulphate (NiSO4 ·6H2O, ana-
lytic grade; Merck, Darmstadt) was used at final concentrations of
5, 7.5 and 10 µg/ml [20]. The culture and labelling conditions and
other procedures were similar to those used in the autologous
MECLR.
Statistical analysis
The results were analysed with STATA (computer program for
statistical analysis; CRC, Los Angeles, Calif., USA). The tests
used to determine statistical significance were Wilcoxon test (WT)
and Wilcoxon’s signed rank sum test (WSRT).
Results
Immunophenotyping of peripheral blood cells
The absolute number of peripheral blood leucocytes, lym-
phocytes and monocytes fell within the normal range in
all psoriasis patients. The absolute number (mean ± SD)
of activated peripheral blood T cells was increased in the
majority of the patients: 199 ± 62 µl CD3+/CD25+ cells
and 173 ± 76 µl CD3+/HLA-DR+ cells, as compared with
an average of 100/µl in healthy individuals (P < 0.01, WT,
n = 12). The number of TcRγδ+ T lymphocytes, CD5+ B
cells and LFA-1α+, LFA-1β+, ICAM-1+, LFA-3+, OKM1+,
CD36+ and IL-1β+ leucocytes did not differ significantly
from those of controls.
Immunophenotyping of ECS
In the ECS of psoriatic lesions, 3.2 ± 0.5% (mean ± SD)
CD45+ cells were observed, but no TcRγδ+ cells. In ECS
of psoriatic skin, the numbers of CD36+, ICAM-1+ and
IL-1β+ cells were clearly increased as compared with ECS
of uninvolved psoriatic and healthy control skin. Im-
munofluorescence microscopy showed that ECS of le-
sional psoriatic skin contained 23 ± 12% CD36+, 31 ±
14% ICAM-1+ and 57 ± 21% IL-1β+ cells (Table 2; P <
0.02, WT, when compared with ECS of normal control
skin). In all experiments the proportions of psoriatic EC
that were positive for both CD45 and CD36 after double
staining were less than 1%. ECS of uninvolved skin from
psoriasis patients contained 0–2% CD36+ and ICAM-1+
cells, but 12 ± 3% IL-1β+ cells (P < 0.05, WT, when com-
pared with ECS of normal control skin). ECS control skin
contained a mean of 0.5 ± 0.1% (range 0–2%) CD36+ and
ICAM-1+ cells, and 4 ± 0.5% IL-1β+ cells (Table 2).
Blocking of the autologous MECLR 
with mAb to adhesion molecules
The functional role of adhesion molecules was investi-
gated by adding antibodies to the autologous MECLR.
The proliferative responses obtained were compared with
the proliferative responses of the ‘untreated’ MECLR.
The results obtained using mAbs specific for the adhesion
molecules CD2 (LFA-2/T11), CD11a (LFA-1α), CD18
(LFA-1β), CD54 (ICAM-1) and CD58 (LFA-3) are shown
in Fig.1. These mAbs clearly and consistently inhibited
the autologous MECLR (P < 0.0025, WSRT). The isotype
control mAb had no effect in this in vitro system. The
mean ± SEM [3H]TdR incorporation expressed as cpm in
the autologous MECLR in the presence of IgG1 and
IgG2a control mAbs were 21277 ± 3095 and 20831 ±
3217 (n = 10), respectively, which did not differ signifi-
cantly from the untreated MECLR.
Table 2 CD36 (OKM5)+, CD54 (ICAM-1)+ and IL-1β+ EC in le-
sional, uninvolved psoriatic skin and in healthy control skin. Val-




(n = 15) (n = 8) (n = 10)
CD36+ 23 ± 12% 0.3 ± 0.1% 0.5 ± 0.1%
ICAM-1+ 31 ± 14% 0.6 ± 0.1% 0.5 ± 0.1%
IL-1β+ 57 ± 21% 12 ± 3% 4 ± 0.5%
Blocking of the autologous MECLR 
with an IL-1β-specific antiserum
The IL-1β-specific antiserum resulted in a consistent inhi-
bition (mean 35 ± 14%, P < 0.002, WSRT) of the autolo-
gous MECLR (Fig.2). The controls comprised EC prein-
cubated with IgG2a isotype control mAb, 1% normal rab-
bit serum, a goat IL-6-specific antiserum and anti-HLA-
DR mAb prior to the autologous MECLR. Anit-IL-6 anti-
serum had no effect on the autologous MECLR, whereas
anti-HLA-DR mAb drastically inhibited the reaction 
(91 ± 8%, P < 0.002, WSRT; Fig. 2). The mean ± SEM
[3H]TdR incorporation in the autologous MECLR in the
presence of IgG2a isotype control mAb and 1% normal
rabbit serum were 20 831 ± 3217 and 23 682 ± 2644 (n =
10), respectively. These values did not differ significantly
from the results from the untreated MECLR. When the
same antibodies and highly purified AET-SRBC-T lym-
phocytes from three psoriatic patients were used in the au-
tologous MECLR, identical results were obtained.
Furthermore, as a control, autologous EC preincubated
with anti-IL-1β antiserum were used to present nickel to
highly purified peripheral blood T lymphocytes from
eight different patients with proven contact dermatitis to
nickel. In these experiments the anti-IL-1β antiserum caused
varying effects. A mean inhibition of 9% in three cases
and a slight increase in the proliferative response of 16%
in five cases were observed. The results in these cases
were in clear contrast to the consistent inhibitory effects
obtained in the autologous MECLR with psoriatic sam-
ples.
Depletion of CD36+ cells from psoriatic ECS
Depletion of CD36+ cells using an immunomagnetic
rosetting technique was reproducible with an almost com-
plete removal of CD36+ cells from the ECS. After deple-
tion, ECS of psoriatic lesions, contained 0–0.5% CD36+
cells as determined by immunofluorescence microscopy.
As shown in Table 3, the removal of CD36+ cells did not
significantly affect the autologous MECLR. In three cases
a slight decrease and in six cases varying increases in the
proliferative responses were observed. The results of con-
trols using IgG1 mAb are shown in Table 3.
Discussion
The increased expression of CD36 and ICAM-1 observed
in this study in psoriatic lesions has also been observed in
previous studies on psoriasis by others. Increased CD36
71
Fig. 1 The effect of blocking with anit-LFA mAb on the autolo-
gous MECLR. Each bar represents the mean ± SEM [3H]TdR in-
corporated in the autologous MLR, MECLR and blocked MECLR
with samples from 12 patients. All mAbs significantly inhibited
the autologous MECLR (P < 0.0025, WSRT). The mean ± SEM
[3H]TdR incorporation in the autologous  MECLR in the presence
of IgG1 and IgG2a isotype control mAbs was 21 277 ± 3095 and
20831 ± 3217 (n = 10), respectively, which did not differ signifi-
cantly from the values from the untreated MECLR
Table 3 The effect of depletion of EC positive for CD36 (OKM5)
on the autologous MECLR with samples from psoriatic patients.
Values represent the mean ± SEM [3H]TdR incorporation of quadru-
plicate cultures. The source and concentration of the anti-CD36 and
control mAb used are shown in Table 1 (NT not tested)
Pa- Proliferation (cpm)
tient
no. Non-depleted EC CD36-depleted EC
PBMC MECLR MECLR IgG1 control
1 944 ± 175 24636 ± 2536 27 351 ± 1605 NT
2 484 ± 180 16196 ± 1628 19 029 ± 1254 14 384 ± 1945
3 1773 ± 862 15369 ± 4759 21 843 ± 6830 20 707 ± 3208
4 613 ± 206 20940 ± 2132 24 911 ± 2037 18 653 ± 2911
5 1093 ± 223 16428 ± 1452 14 052 ± 1175 19 479 ± 1613
6 951 ± 317 15324 ± 1596 18 773 ± 2567 NT
7 2537 ± 763 37442 ± 7059 39 190 ± 4872 43 810 ± 6459
8 1319 ± 341 26635 ± 1755 24 860 ± 2199 NT
9 1161 ± 128 15496 ± 1235 12 864 ± 1307 NTFig. 2 The effect of blocking with anti-IL-1β, anti-IL-6 and anti-
HLA-DR antibodies on the autologous MECLR. Each bar repre-
sents the mean ± SEM [3H]TdR incorporated in the autologous
MLR, MECLR and blocked MECLR with samples from 15 patients.
The anti-HLA-DR mAb and anti-IL-1β polyclonal antiserum signif-
icantly inhibited the autologous MECLR (P < 0.002, WSRT). The
mean ± SEM [3H]TdR incorporation in the autologous MECLR in
the presence of IgG2a isotype control mAb and 1% normal rabbit
serum were 20831 ± 3217 and 23682 ± 2644 (n = 10), respec-
tively. These values did not differ significantly from the values
from the untreated MECLR
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expression has also been described in other inflammatory
dermatoses, suggesting upregulation of these molecules
by proinflammatory cytokines [2, 3, 11]. The microscopic
appearance of CD36+ EC in ECS was that of medium to
large-sized keratinocytes. The low number of CD45+/
CD36+ EC as determined by double-labelling, and their
expression in the upper epidermal layers indicate that the
majority of the CD36+ cells in lesional skin are ker-
atinocytes. Although, intense expression of CD36 was ob-
served on a considerable proportion of psoriatic ker-
atinocytes, the results of the depletion experiments sug-
gest that CD36+ keratinocytes do not serve as accessory
cells in the autologous MECLR. These results and those
of a previous study on the autologous MECLR in psoria-
sis suggest that keratinocytes do not serve as accessory
cells in this system. This may be explained by the fact that
a limited number of keratinocytes in psoriatic lesions ex-
press MHC class II antigens which seem necessary for
such an accessory function [26]. Consistent with this is
the profound inhibitory effect of anti-HLA-DR mAb in
the autologous MECLR (Fig. 2).
The results of the blocking studies using mAbs to the
integrin family of adhesion molecules and their ligand(s)
indicate a clear costimulatory role of these molecules in
the autologous MECLR in psoriasis. This finding is con-
sistent with the reported costimulatory function of these
adhesion molecules in comparable in vitro systems using
skin APC [25]. In accordance with the decreased stimula-
tion of T cells after addition of anti-LFA mAb, in this
study a reduced cell–cell aggregation (less clustered cells)
was observed in the mixed cultures upon light-micro-
scopic examination. Further illustrations of the impor-
tance of adhesion molecules in psoriasis are the LFA-me-
diated adherence of peripheral blood lymphocytes to
cryostat sections of psoriatic lesions and the activation of
keratinocytes by this adherence [7, 24]. Taken together,
the results of our investigations indicate that in psoriatic
patients, LFA-3 and ICAM-1 membrane molecules on
HLA-DR+/CD1a– epidermal APC deliver costimulatory
signals to T cells in the autologous MECLR [19]. In the
same system, the role of ICAM-1+ keratinocytes seems re-
stricted to co-immobilization of T lymphocytes resulting
in cluster formation, and consequent T cell activation by
epidermal APC. However, under certain in vitro condi-
tions, keratinocytes may serve as accessory cells in T-cell-
mediated responses [16, 23]. IFN-γ-treated cultured kera-
tinocytes serve as accessory cells in an autologous mAb
T-cell-mediated response to bacterial superantigen, PHA
and immobilized anti-CD3 mAb, but not in an allogeneic
T-cell-mediated response [16]. In this type of stimulation of
autologous T cells, costimulatory signals are delivered via
the LFA-1/ICAM-1 pair of adhesion molecules. It would be
useful to investigate the effects of nominal or autologous
antigen in this system to further delineate its in vivo rele-
vance. MHC class I- and class II-independent, LFA-1/
ICAM-1-mediated stimulation of allogeneic and autolo-
gous PBMC by PMA-treated cultured keratinocytes, but ab-
rogation of their stimulatory capacity by IFN-γ pretreat-
ment, has also been reported [23].
The observed inhibition by the antibody to IL-1β indi-
cates that IL-1β+ psoriatic EC deliver costimulatory sig-
nals to autologous T lymphocytes in the MECLR. The cel-
lular source of the costimulatory IL-1 in the autologous
MECLR remains unclear, because both keratinocytes and
dendritic epidermal APC are known to produce this cy-
tokine [4, 9]. Stimulation via peripheral blood monocyte-
derived IL-1 appeared to be negligible in our system be-
cause of (1) the consistent, identical results when highly
purified T cells were used and (2) the diverse effects of
the same antibody to IL-1β in tetanus toxin and nickel-
stimulated T cells using EC as APC. The functional rele-
vance of IL-1 has been well documented in several in
vitro systems, but its role in chronic inflammatory skin
disease is not yet fully understood. Indirect indications of
its importance are the findings that dendritic cell-derived
IL-1β is an essential molecule required for the initiation
of primary immune responses in skin and that skin-de-
rived IL-1 is a potent inflammatory agent in human skin
in vivo [5, 9]. The accessory function of IL-1 in the autol-
ogous MECLR and its elevated expression on EC from
uninvolved and lesional skin observed in this study em-
phasizes the relevance of the reported IL-1 dysregulation
in psoriasis [8].
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